Kisqali (with fulvestrant) (ribociclib with fulvestrant)

pCPA File Number: 21218
Negotiation Status:
Concluded with an LOI
Indication(s):
Advanced or Metastatic Breast Cancer
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
PC0195-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: